

Enhancing Awareness and Access

Nancy Roach, Fight Colorectal Cancer

Disclaimer

The views and opinions expressed in this presentation are those of the individual presenter and do not necessarily reflect the views of the Clinical Trials Transformation Initiative (CTTI) or the U.S. Food & Drug Administration (FDA).




Tom Marsilje, PhD aka Dr. Tom





Stage IV





Promise of Immunotherapy....



Wall Street Journal, December 4 2014




Search terms:

- Metastatic CRC
- Recruiting
- Not yet recruiting

270 trials total

What about phase 1 trials for solid tumors?







"As a patient, I had no interest in participating in a trial which had both the highest risk of failure as well as limited long-term benefit, even if the experimental therapy worked as designed. I knew that I may only have one shot at a trial, so I wanted to choose that trial wisely and make that potentially single shot count the most!" – Dr. Tom Marsilje



What does that mean?

- MSS tumors: Majority of patients (>95%) who have micro-satellite stable tumors (MSS)
- No trials in China: at that point, 4-5 years ago, Tom had concerns about listing trials that most people probably wouldn't be able to access



What does that mean?


- Highest "potential" chance of benefit: Chance for a durable response, even if it's a small chance. Immunotherapy trials* are characterized as highest "potential."
- Lowest "potential" chance of trial failure: Trials can fail due to either safety or lack of efficacy. CRC trials that have advanced to Phase 2 or Phase 3* are characterized as lowest "potential" for failure.
- * means parameters will evolve as science evolves



CHARLIE **ROSE**

SEARCH BY PERSON, TOPIC OR YEAR

ALL POLITICS WORLD ENTERTAINMENT TECH MORE *









Technology ~

Company ~

Publications


Careers

Blog

Hacking for Good: Improving Access to Clinical Trials

By Ben Holzman


Engineering & Product





Late Stage MSS-CRC Trial Finder

A Curated List Powered by Patients



MEDICAL DISCLAIMER

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website. Go here to support Fight CRC research efforts.

http://trialfinder.fightcrc.org/



Curation Process

- Level 1 Curation
 - Research advocate team
 - Is this for stage 4 MSS CRC patients?
 - Is it immunology or phase 2 / phase 3 trial?
 - We now accept trials from China
 - In, Out, or Maybe



Curation process

- Level 2 curation
 - Super advocates with scientific background and scientist support
 - Generally decide questions around potential impact or complex eligibility criteria
 - In or Out, with comments




Impact of curation

Search terms:

- Metastatic CRC
- Recruiting
- Not yet recruiting

375 trials total vs 270 in CT.gov



MEDICAL DISCLAIMER

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website. So here to support Fight CRC research efforts.




Utilization since May 2017

- Over 14,000 users have utilized the tools, amounting to nearly 26,000 unique searches.
- Aside from the United States, the countries with patients using the tool the most are the United Kingdom and China.
- Users spend over two and a half minutes per session and navigate between two and three pages each session



Tom Marsilje, 1972-2017





Thank you to ...

- Maia Walker, the wizard behind the curtain
- FightCRC research advocates who curate
- Flatiron who programmed
- Erika Hanson Brown, the Mayor of Colontown
- Reece Garcia, the FightCRC staff person who juggles (and all the FightCRC staff who believed and helped)



Questions?

Nancy.Roach@FightColorectalCancer.org

